By Amanda Gardner
HealthDay Reporter
TUESDAY, April 10 (HealthDay News) — A leading U.S. government panel has renewed its 2004 recommendation that women at average risk for ovarian cancer not get screened for the disease.
The currently used blood test and transvaginal ultrasound may cause more harm than benefit for those patients, according to draft recommendations issued Tuesday by the U.S. Preventive Services Task Force.
TUESDAY, March 27 (HealthDay News) — Women with ovarian cancer who are black, either uninsured or Medicare recipients, or who have annual incomes of less than $35,000 are more likely to receive poorer-quality care, a new study shows.
Researchers found these racial and socioeconomic disparities in ovarian cancer care also are associated with worse odds of surviving for five years after their cancer diagnosis.
WEDNESDAY, Feb. 22 (HealthDay News) –
Women with a history of endometriosis have a significantly increased risk of developing three types of ovarian cancer, according to a new study.
Endometriosis is a disorder in which cells from the lining of the uterus grow in other areas of the body. It affects about 10 percent of women of reproductive age.
By Kathleen Doheny
HealthDay Reporter
TUESDAY, Jan. 24 (HealthDay News) — Genetic mutations known as BRCA1 and BRCA2 raise the risk of getting ovarian cancer, but new research shows that those same mutations may boost a woman’s odds of surviving the deadly disease.
Women with invasive epithelial ovarian cancer who carry the mutations have a better prognosis than women without the genetic variations, according to an analysis of 26 previous studies. The BRCA2 carriers, in particular, had a better five-year survival rate.
By Serena Gordon
HealthDay Reporter
WEDNESDAY, Dec. 28 (HealthDay News) — Two new studies suggest that the drug Avastin may lengthen progression-free survival by about four months for women with ovarian cancer.
What isn’t clear yet is whether adding Avastin (bevacizumab) will make a difference in overall survival. One study suggested it would, while the other study didn’t find a difference in overall survival between two treatment groups.
THURSDAY, Dec. 8 (HealthDay News) — Some women who inherit the BRCA1 or BRCA2 breast and ovarian cancer genes from their father may be diagnosed with breast cancer nearly a decade earlier than those who inherit the genes from their mother, a new study indicates.
Researchers examined the family trees of 128 breast or ovarian cancer patients with the BRCA1 or BRCA2 mutations to determine the origins of the patients’ cancer genes.
By Maureen Salamon
HealthDay Reporter
TUESDAY, Nov. 8 (HealthDay News) — A vaccine that coaxes the body to attack tumor cells has shown promise in a small study of advanced breast and ovarian cancer patients, improving overall survival times and stopping the disease for a handful of breast cancer patients.
The PANVAC vaccine, administered to 26 women through monthly shots, helped the body’s immune system recognize proteins produced specifically by cancer cells, said study author Dr. James Gulley, director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the U.S. National Cancer Institute.
THURSDAY, Oct. 27 (HealthDay News) — Women who undergo ovarian stimulation to produce extra eggs for in-vitro fertilization (IVF) are at increased risk for a type of growth known as “borderline ovarian tumors,” new research suggests.
Borderline ovarian tumors are typically not aggressive, according to the U.S. National Cancer Institute. Even if the tumor does spread, the vast majority of women survive borderline ovarian tumors.
SUNDAY, Aug. 21 (HealthDay News) — An experimental drug that’s shown promise against ovarian cancer caused by mutations in the BRCA1 or BRCA2 genes may also be effective against ovarian cancer not caused by those gene mutations, according to a new study.
Olaparib blocks the activity of a protein called poly ADP ribose polymerase (PARP). Both PARP and BRCA proteins are involved in DNA repair. Clinical trials of olaparib in patients with BRCA 1 and 2 mutations have yielded promising results, the study authors noted.
By Serena Gordon
HealthDay Reporter
WEDNESDAY, Aug. 17 (HealthDay News) — Researchers have found an antibody that might someday be useful in identifying women who have a higher risk of ovarian cancer, or possibly diagnosing early ovarian cancer.
This particular antibody, which was detected in blood, develops as an immune system response to a protein called mesothelin. This protein is present in advanced ovarian cancer. Although mesothelin is found in normal tissue, it’s found in abundance in ovarian cancer cells.
| Text Size: |  |
|
